Aquestive Therapeutics 3Q 2026: Revenue $7.6M, Net loss $16.5M, EPS $(0.13) — 10-Q Summary

What happened

Aquestive Therapeutics reported third-quarter 2026 revenue of $7.6M, down 41% from a year earlier as manufacture and supply revenue declined. Its net loss was $16.5M, compared with a $15.4M loss in the prior-year quarter, while diluted earnings per share was $(0.13), versus $(0.14).

Confirmed

Global impact / market context

Lower quarterly supply revenue alongside a larger net loss indicates weaker recent sales and greater losses, which may increase pressure on cash available if the pattern continues. However, higher nine-month revenue from royalties and potential future product launches offer possible revenue sources, subject to approvals and execution.

Analyst inference

The results combine near-term sales weakness with prospective commercial and development milestones. The FDA accepted the Anaphylm application again and set a March 16, 2027 decision goal date; until approval, the planned U.S. launch and related sales remain uncertain rather than current revenue.

Analyst inference

What to watch

1. Track whether lower Suboxone supply sales and manufacture revenue persist in later quarters, since continued declines could reduce revenue before potential new product sales begin. Analyst inference
2. Watch for the FDA decision on Anaphylm by its March 16, 2027 PDUFA goal date; PDUFA is the agency’s target date for an application decision. Confirmed
3. Check whether Eton’s Libervant commercialization arrangement receives regulatory approvals and whether Aquestive begins manufacturing and supplying the product as expected. Analyst inference

Evidence

• Original source link unavailable